Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IL-17: Pushing The Limits Of A Drug Target

This article was originally published in Start Up

Executive Summary

A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.

You may also be interested in...



Novartis Targets Leading MS Role With Gilenya, BAF312 And IL-17 Pathway

Novartis aims to build a leading role in multiple sclerosis by developing new agents now in Phase III, progressing promising early stage assets and by using new technologies to measure the disease.

Lilly’s Ixekizumab Results More Than Skin Deep In Psoriasis Study

The big pharma presented positive Phase III data for the psoriasis drug when compared with placebo and the current standard of care, Amgen’s Enbrel. Lilly plans to submit the IL-17 inhibitor for approval by mid-2015.

Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review

Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approval. Investigators note prevalence of Candida infections in patients on the Novartis drug.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092522

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel